| abstract |
Imidazolidine derivatives of the formula (I) are disclosed, in which B, E, W, Y, R, R2, R3, R30, e and h are as defined in the specification. The compounds of the formula (I) are suitable for treating inflammatory disease, for example rheumatoid arthritis, or allergic diseases. The compounds of the formula (I) are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, which belongs to the integrin group. They are generally suitable for treating diseases which are caused by, or associated with, an undesirable degree of leukocyte adhesion and/or leukocyte migration or in which cell-cell or cell-matrix interactions, which are based on the interactions of VLA-4 receptors with their ligands, play a role. A process for preparing the compounds of the formula (I) is also disclosed. |